Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01606748 · ClinicalTrials.gov registry record · Phase 2
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01606748 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants.
The verdict
NCT01606748, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- BIOLOGICAL Necitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01606748
The ClinicalTrials.gov registry entry for NCT01606748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01606748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01606748 about?
NCT01606748 is a clinical study titled "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin". The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.
What is the current status of trial NCT01606748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2012-08. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01606748?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Necitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01606748?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.